Tetratherix (ASX:TTX) has officially listed on the Australian Securities Exchange after raising $25 million in its initial public offering (IPO).
Tetratherix is an Australian medical technology company developing advanced biomaterial solutions to transform the treatment of complex diseases. Its polymer platform enables the targeted delivery of cells, drugs, and biologics.
The company stated that the listing marks the beginning of a new chapter as it transitions to a publicly listed company with a clear purpose: to accelerate the development and commercialisation of its polymer platform, thereby.
The company’s Tetramatrix is the world’s first biostealth fluid matrix. It is being used to develop clinical products applicable across numerous areas, including bone regeneration, tissue spacing and tissue healing. It stated that these markets have a total addressable opportunity of approximately US$6.8 billion.
The Tetramatrix material is an injectable fluid that, upon administration, forms a 3D matrix that physically integrates and adheres to the target tissue. It is modular in nature, possesses similar properties to natural tissue and gradually bioresorbs in the body once it has served its purpose. Other benefits of Tetramatrix include its minimally invasive delivery, low cost, scalable production and the ability to seamlessly integrate it into existing workflows. Another advantage is its medical device classification, which facilitates faster regulatory approval processes compared to drugs or therapeutic candidates.
The company anticipates having its first two products on the market in the first half of 2026, along with a commercial pathway that will enable FDA clearance of three additional products over the next four years.
The offer consisted of $25 million of primary capital through the issuance of 8,680,000 new shares at $2.88. The IPO values Tetratherix at $145 million.
Tetratherix CEO Will Knox said, “An ASX listing has long been a goal on our journey as a business, and our near term growth trajectory and commercial momentum make this the right time. On behalf of our leadership team, we would like express our gratitude to all of our staff, investors and partners who have all played a role in helping us reach this exciting milestone.
“This IPO is not an endpoint or an exit strategy, rather a foundation upon which we will accelerate product development, expand our global clinical footprint and scale manufacturing and commercial operations.”